It is therefore incumbent upon us to optimize our luteal phase protocols to improve implantation rates and enable fresh embryo transfers while still taking advantage of GnRH agonist trigger to decrease the risk of OHSS. This evidence concerns the gene GNRH1 and ovarian hyperstimulation syndrome.